New Classification System Predicts Immunotherapy Response in Liver Cancer Patients with β-Catenin Mutations
核心洞察
Researchers have developed a functional classification system for CTNNB1 (搜索) mutations that can predict immunotherapy (搜索) response in hepatocellular carcinoma (搜索) patients.
The study analyzed 342 genetic variants and classified mutations as "strong" or "weak" based on their activation of the WNT/β-catenin pathway (搜索) using CRISPR-based genome editing.
Strong mutations create immunosuppressive environments resistant to therapy, while weak mutations allow immune cell infiltration and better treatment response.
A groundbreaking study has revealed why some hepatocellular carcinoma (搜索) (HCC (搜索)) patients with β-catenin (搜索) mutations respond to immunotherapy (搜索) while others do not, providing a new tool for precision medicine in liver cancer treatment. The research, conducted by the IDIBAPS Translational Research in Hepatic Oncology group, offers the first systematic classification of CTNNB1 (搜索) mutations based on their functional impact on immune response.
Novel Mutation Classification System
The study systematically analyzed 342 genetic variants located in exon 3 of the CTNNB1 (搜索) gene, where most mutations are concentrated. Using an experimental CRISPR-based genome-editing strategy, researchers evaluated each variant's ability to activate the WNT/β-catenin (搜索) signaling pathway and determined its impact on immune profiles.
The results enabled classification of CTNNB1 (搜索) mutations into two distinct groups:
Strong mutations cause intense activation of the WNT/β-catenin pathway (搜索), generating an immunosuppressive environment that prevents immune cells from entering the tumor, making it more resistant to immunotherapy (搜索).
Weak mutations activate the pathway to a limited extent and allow immune cells to infiltrate the tumor, which is associated with better response to immunotherapy (搜索).
Clinical Validation and Implications
The classification system was validated in 124 samples from HCC (搜索) patients, confirming that the intensity of WNT/β-catenin pathway (搜索) activation is a determining factor in immunotherapy (搜索) response. This finding addresses a critical knowledge gap, as mutations in CTNNB1 (搜索) are present in 30% of HCC cases, with most presenting a "cold" immune phenotype characterized by absence of immune cell infiltration and resistance to immunotherapy.
However, previous research by the same group had shown that a third of HCC (搜索) cases with CTNNB1 (搜索) mutations display a "hot" immune profile with immune cell presence and response to immune checkpoint inhibitors (搜索). The molecular mechanisms responsible for this difference were previously unknown.
Broader Applications in Oncology
While the study focuses on HCC (搜索), the results have relevance for other solid tumors with CTNNB1 (搜索) mutations, including endometrial, colon, and central nervous system tumors (搜索). The research constitutes a reference resource for interpreting the functional diversity of these mutations across different cancer types.
Advancing Precision Medicine
"This discovery opens the door to personalised medicine strategies for hepatocellular carcinoma (搜索). Knowing the type of β-catenin (搜索) mutation can help predict the response to immunotherapy (搜索) and to design more effective therapeutic combinations," said Josep M. Llovet, leader of the IDIBAPS group and chair professor of Medicine at the University of Barcelona, ICREA professor, and chair professor of Medicine at the Icahn School of Medicine at Mount Sinai.
Co-author Roser Pinyol emphasized the clinical significance: "We have demonstrated that not all mutations in CTNNB1 (搜索) are the same. This information is key for stratifying patients and optimising treatments, especially in a context where immunotherapy (搜索) is an increasingly relevant option."
Future Therapeutic Development
The study not only provides a molecular explanation for variability in immunotherapy (搜索) response in HCC (搜索) but also offers a tool for identifying patients who can benefit most from these treatments. The results could have significant implications for developing new drugs aimed at modulating the WNT/β-catenin pathway (搜索).
The research team included Agavni Mesropian, Albert Gris-Oliver, Roser Pinyol, and Josep M. Llovet from the IDIBAPS Translational Research in Hepatic Oncology group, representing a collaborative effort to advance personalized cancer treatment approaches.